title: Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study).
abstract: OBJECTIVE
  To identify the determinants of anti-TNF-naive patients' preferences for the route of administration of anti-TNF agents.
  
  
  METHODS
  The study was carried out in 50 Italian rheumatology centres (802 patients). All patients completed a 31-item questionnaire addressing their perceptions of current treatment and the preferences for treatment with anti-TNF agents. Statistical methods included analysis of variance (ANOVA), t-test and chi-square test.
  
  
  RESULTS
  The response rate to the questionnaire was 97.6%. At the time of the survey, 310 (39.9%) patients were dissatisfied with current treatments, owing to inefficacy, side effects and inconvenience of administration. The i.v. and s.c. routes of administration were preferred by 50.2 and 49.8%, respectively. No significant difference was found in patients by gender, age, RA duration or number of drugs used. Reasons for the choice of i.v. administration were the safety of treatment at the hospital and the reassuring effect of physician presence. The s.c. administration was chosen for the convenience of treatment and in particular for home treatment. Patients dissatisfied with current therapy due to side effects preferred s.c. administration (P = 0.029), whereas patients choosing the i.v. route had slightly higher scores on 'today pain' (P = 0.047) and 'articular pain' (P = 0.023) of the Rheumatoid Arthritis Disease Activity Index (RADAI).
  
  
  CONCLUSIONS
  Both i.v. and s.c. treatments were well accepted by patients. However, treatment choice has to be discussed with patients, as individual preference seems to be determined by personal attitudes towards safety and convenience, by past experience and by the perception of current disease status.
authors.affiliation: Rheumatology Unit, M. Scarlato Hospital, Scafati, 5, Via Passanti, 84018 Scafati (Sa), Italy. scarpasa@tin.it
authors.forename: Salvatore
authors.initials: S
authors.lastname: Scarpato
authors.forename: Marco
authors.initials: M
authors.lastname: Antivalle
authors.forename: Ennio G
authors.initials: EG
authors.lastname: Favalli
authors.forename: Francesca
authors.initials: F
authors.lastname: Nacci
authors.forename: Sabrina
authors.initials: S
authors.lastname: Frigelli
authors.forename: Francesca
authors.initials: F
authors.lastname: Bartoli
authors.forename: Laura
authors.initials: L
authors.lastname: Bazzichi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Minisola
authors.forename: Marco
authors.initials: M
authors.lastname: Matucci Cerinic
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000523:psychology; D002755:Choice Behavior; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D055104:Infusions, Subcutaneous; D007558:Italy; D008297:Male; D008875:Middle Aged; D057240:Patient Preference; D012646:Self Administration; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha